Systemic therapy is the first-line treatment option for advanced HCC, encompassing targeted therapy, such as tyrosine kinase inhibitors (TKIs), immune-checkpoint inhibitors (ICIs), including programmed cell death-1 (PD-1) inhibitors, and combined therapies (Xu et al., 2018). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.